Original Source(s)
Related Content
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min
Bloodstream Infection Results in Hours
Early results support further clinical validation of a direct-from-blood diagnostic workflow
September 25, 2026
-
3 min
Tiny Heart Samples, Detailed Protein Data
A one-pot method detects and characterizes phospholamban proteoforms from biopsy-scale samples
September 29, 2026
-
3 min